Compounds > 4,4'-dithiodimorpholine
Page last updated: 2024-09-21

4,4'-dithiodimorpholine

Description

4,4'-dithiodimorpholine: rubber vulcanizing agent causing occupational dermatitis; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7648
CHEMBL ID582932
SCHEMBL ID137538
MeSH IDM0062169

Synonyms (96)

Synonym
brn 0126214
dimorpholine n,n'-disulfide
vanax a
ccris 8923
morpholine, n,n'-disulfide-
n,n'-dithiodimorfolin [czech]
einecs 203-103-0
sanfel r
ai3-08625
morpholinodisulfide
hsdb 5351
deovulc m
vulnoc
4,4'-dithiobismorpholine
di(morpholin-4-yl) disulphide
morpholine, 4,4'-dithiodi-
nsc 65239
dimorpholino disulfide
morpholine,4'-dithiodi-
bismorpholino disulfide
n,n-dithiodimorpholine
morpholine,4'-dithiobis-
sulfasan r
morpholine disulfide
sulfasan
4,4'-dithiomorpholine
n,n'-bismorpholine disulfide
wln: t6n dotj ass-at6n dotj
disulfide, dimorpholino-
morpholino disulfide
n,n'-dithiodimorpholine
usaf ek-t-6645
usaf b-17
dithiobis(morpholine)
nsc-65239
accel r
4,4'-dithiobis(morpholine)
dithiobismorpholine
dimorpholine disulfide
morpholine, 4,4'-dithiobis-
103-34-4
4-(morpholinodisulfanyl)morpholine
4,4'-dithiodimorpholine
nsc65239
NCIOPEN2_003134
n,n'-dimorpholine disulfide
n,n'-dithiobis(morpholine)
D0282
inchi=1/c8h16n2o2s2/c1-5-11-6-2-9(1)13-14-10-3-7-12-8-4-10/h1-8h2
hlbzwyxlqjqbku-uhfffaoysa-
4-morpholin-4-yldisulfanylmorpholine
4-(morpholin-4-yldisulfanyl)morpholine
dithiodimorpholine
CHEMBL582932
FT-0657982
NCGC00249116-01
tox21_303110
cas-103-34-4
dtxsid8026698 ,
dtxcid706698
NCGC00257082-01
tox21_201775
NCGC00259324-01
4,4-dithiodimorpholine
bdbm50414924
unii-m786p489yf
n,n'-dithiodimorfolin
ec 203-103-0
m786p489yf ,
4-27-00-00613 (beilstein handbook reference)
AKOS015897388
4,4'-disulfanediyldimorpholine
STL326287
SCHEMBL137538
dithiodimorpholine, 4,4'-
4,4'-dithiodimorpholine [hsdb]
4,4'-dithiodimorpholine [mi]
morpholine n,n'-disulfide
4,4'-dimorpholine disulphide
morpholine, n,n'-disulfide
4-(4-morpholinyldisulfanyl)morpholine #
akrochem accelerator r
naugex sd-1
sulfazan r
dimorpholinodisulfide
bis(4-morpholinyl)disulfide
mfcd00023319
AS-57709
4-(4-morpholinyldisulfanyl)morpholine
1,2-dimorpholinodisulfane
4,4'-dithio-dimorpholine
CS-0196466
4,4/'-dithiodimorpholine
E78171
Q27283591
n,n'-dimorpholinedisulfide

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency70.28560.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency61.03443.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.06170.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency51.45650.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency51.45650.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency32.48410.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency62.35690.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency76.17690.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency72.03480.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.29170.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency46.08760.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency64.67950.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.61440.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency53.98600.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency61.03440.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency64.51170.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.51820.000229.305416,493.5996AID1259244; AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency46.63080.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency76.17690.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.24110.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency43.64120.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.97090.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency45.09770.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency27.16730.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency27.16730.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency62.03920.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.01490.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.02700.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)1,000.00000.00020.59827.0000AID441698
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)11.22020.00091.126810.0000AID441697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID441697Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID477881Antiproliferative activity against BCA2 and ER deficient human MDA-MB-231 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477883Antiproliferative activity against human T47D cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477884Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID441696Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate at 10 uM by liquid scintillation counting2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID441698Inhibition of human recombinant FAAH-maltose binding protein2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.
AID477880Antiproliferative activity against human MCF7 cells expressing BCA2 and estrogen receptor after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
AID477882Antiproliferative activity against human MDA-MB-231 cells expressing BCA2 and ERalpha after 72 hrs by MTT assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
disulfiram[no description available]medium20organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
thiram[no description available]medium10organic disulfideantibacterial drug;
antifungal agrochemical;
antiseptic drug
bis(1-piperidylthiocarbonyl)disulfide[no description available]medium20
tetramethylthiuram monosulfide[no description available]medium10
methyl diethyldithiocarbamate[no description available]medium10
arachidonyltrifluoromethane[no description available]medium10fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
cay 10499[no description available]medium10carbamate ester
methyl arachidonylfluorophosphonate[no description available]medium10phosphonic ester
urb602[no description available]medium10
ly2183240[no description available]medium10biphenyls
azodicarbonamide[no description available]medium10organic molecular entity
lopinavir[no description available]medium10amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
diamide[no description available]medium101,1'-azobis(N,N-dimethylformamide)
pyrimidinones[no description available]medium10
isoprene[no description available]medium30alkadiene;
hemiterpene;
volatile organic compound		plant metabolite
benzothiazole[no description available]medium10benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
benzenesulfohydrazide[no description available]medium10
thiazoles[no description available]medium301,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
captax[no description available]medium20aryl thiol;
benzothiazoles		carcinogenic agent;
metabolite
n-oxydiethylene-2-benzothiazole sulfenamide[no description available]medium20
morpholine[no description available]medium20morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Autosome0low10
Abnormalities, Chromosomal0low10
Abnormalities, Chromosome0low10
Abnormalities, Drug-Induced0low10
Autosome Abnormalities0low10
Breast Cancer0low10
Breast Carcinoma0low10
Breast Neoplasms0low10
Breast Tumors0low10
Cancer of Breast0low10
Cancer of Cervix0low10
Cancer of the Breast0low10
Cancer of the Cervix0low10
Cancer of the Uterine Cervix0low10
Cervical Cancer0low10
Cervical Neoplasms0low10
Cervix Cancer0low10
Cervix Neoplasms0low10
Chromosomal Aberrations0low10
Chromosome Aberrations0low10
Chromosome Abnormalities0low10
Cytogenetic Aberrations0low10
Cytogenetic Abnormalities0low10
Drug-Induced Abnormalities0low10
Eye Abnormalities0low10
Fibroma, Shope0low10
HPV Infection0low20
Human Mammary Carcinoma0low10
Human Papillomavirus Infection0low20
Infections, Tumor Virus0low10
Malignant Neoplasm of Breast0low10
Malignant Tumor of Breast0low10
Mammary Cancer0low10
Mammary Carcinoma, Human0low10
Mammary Neoplasm, Human0low10
Mammary Neoplasms, Human0low10
Neoplasms, Breast0low10
Neoplasms, Cervical0low10
Neoplasms, Cervix0low10
Papilloma, Shope0low10
Papillomavirus Infections0low20
Poultry Diseases0low10
Tumor Virus Infections0low10
Tumors, Breast0low10
Uterine Cervical Cancer0low10
Uterine Cervical Neoplasms0low10